Tada, 

Just to clarify....only some patients, not all patients, will exceed 104 weeks of dosing. Full enrollment of the 2400 patients was announced March 19th, 2018, so 104 weeks out for those last patients would be March 2020. I don't think we want to wait that long for the top line data! Of course, there is always the possibility that the SSRA will recommend a change that could lengthen the trial or perhaps an amendment to allow BETonMACE to continue after top line as an open label extension/safety study. Also, sorry but I can offer no help with your statistics question about implications of exceeding 2400 patients. 

BearDownAZ